TSEC:6541

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. More Details


Snowflake Analysis

Mediocre balance sheet with limited growth.

Share Price & News

How has Tanvex BioPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6541 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6541's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-4.9%

6541

-2.3%

TW Biotechs

-0.2%

TW Market


1 Year Return

-20.9%

6541

21.7%

TW Biotechs

28.6%

TW Market

Return vs Industry: 6541 underperformed the TW Biotechs industry which returned 21.7% over the past year.

Return vs Market: 6541 underperformed the TW Market which returned 28.6% over the past year.


Shareholder returns

6541IndustryMarket
7 Day-4.9%-2.3%-0.2%
30 Day-10.5%-7.8%8.8%
90 Day-11.0%-2.8%20.6%
1 Year-20.9%-20.9%22.2%21.7%33.1%28.6%
3 Year-58.3%-58.3%-17.7%-19.2%55.3%37.8%
5 Year-82.8%-82.8%-48.1%-48.6%135.7%94.2%

Long-Term Price Volatility Vs. Market

How volatile is Tanvex BioPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tanvex BioPharma undervalued compared to its fair value and its price relative to the market?

6.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6541's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6541's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6541 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6541 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6541's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6541 is overvalued based on its PB Ratio (6.5x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is Tanvex BioPharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

19.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6541 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6541 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6541 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6541's revenue (143.4% per year) is forecast to grow faster than the TW market (11.1% per year).

High Growth Revenue: 6541's revenue (143.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6541 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Tanvex BioPharma performed over the past 5 years?

-21.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6541 is currently unprofitable.

Growing Profit Margin: 6541 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6541 is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.

Accelerating Growth: Unable to compare 6541's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6541 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 6541 has a negative Return on Equity (-152.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is Tanvex BioPharma's financial position?


Financial Position Analysis

Short Term Liabilities: 6541's short term assets (NT$1.0B) exceed its short term liabilities (NT$308.3M).

Long Term Liabilities: 6541's short term assets (NT$1.0B) exceed its long term liabilities (NT$268.7M).


Debt to Equity History and Analysis

Debt Level: 6541's debt to equity ratio (6.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 6541's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6541 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 6541 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 18% each year


Next Steps

Dividend

What is Tanvex BioPharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6541's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6541's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6541's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6541's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6541's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average board tenure


CEO

Allen Chao (74 yo)

no data

Tenure

NT$20,055,000

Compensation

Dr. Allen Chao, Ph.D., serves as Chief Executive Officer of Tanvex BioPharma, Inc. Dr. Chao served as Senior Advisor at Delos Advisors Limited. He is Founder of Tanvex Biologics, Inc. and serves as its Exe...


CEO Compensation Analysis

Compensation vs Market: Allen's total compensation ($USD716.45K) is above average for companies of similar size in the TW market ($USD196.23K).

Compensation vs Earnings: Allen's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Allen Chao
CEO & Directorno dataNT$20.06mno data
David Hsia
Chief Scientific Officer & Director5.67yrsNT$2.61m0.81%
NT$ 88.0m
Lee-Chiou Chang
Independent Director5.67yrsNT$682.00kno data
Yun Yen
Director5.67yrsNT$25.00k0.10%
NT$ 11.2m
Chuan Shih
Independent Director5.67yrsNT$617.00kno data
Lung-Yen Cho
Director7.75yrsNT$35.00kno data
Lin-Cheng Chen
Director5.67yrsNT$15.00kno data
Jin-Pau Tsai
Independent Director5.67yrsNT$697.00kno data
Horng-Dar Lin
Chairman of the Board2.08yrsNT$6.26mno data

5.7yrs

Average Tenure

74yo

Average Age

Experienced Board: 6541's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.7%.


Top Shareholders

Company Information

Tanvex BioPharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tanvex BioPharma, Inc.
  • Ticker: 6541
  • Exchange: TSEC
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$10.922b
  • Shares outstanding: 311.61m
  • Website: https://www.tanvex.com

Location

  • Tanvex BioPharma, Inc.
  • 802, West Bay Road
  • Grand Pavilion
  • George Town
  • Grand Cayman
  • KY1-1205
  • Cayman Islands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6541TSEC (Taiwan Stock Exchange)YesOrdinary SharesTWTWDAug 2015

Biography

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Its products ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 08:39
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.